what the hack you are talking about? why does vintafolide should be discussed on COMP meeting? it will be on CHMP. so please do not pump with wrong info.
"The Committee for Orphan Medicinal Products (COMP) is the committee at the European Medicines Agency that is responsible for reviewing applications from people or companies seeking 'orphan-medicinal-product designation'."
Go to EMA site and look at the Agenda for the Jan COMP meeting. 3 Endocyte Europe, Folcepri,Neocepri and Vynfinit were all on the agenda for the meeting. That is not pumping, you might want to do a little DD before you post
Endocyte's compounds have advanced in their valuation stage at COMP to 'prior to adoption of CHMP opinion' (this COMP meeting in January) from 'on-going procedures' (previous COMP meeting in December): google respective key words to pick up COMP's pdf files
We can now assume that a CHMP decision is due in not too short a distance - I bet on positive recommendation by CHMP
Yup, I love what I'm seeing in the options on ECYT. You would have to be asking for punishment going into next week short. How high to you think this goes -- obviously $20+, but do you see the 30's next week as possible? Also, just thought I'd give you a stock tip, different sector -- TTS is doing really well, revenue, margins, some real nice upside on that the next few months.